Translational/personalized medicine, pharmaco/surgico/radiogenomics, lymphatic spread of cancer, and medical ignoromes

Authors

  • Marlys H. Witte MD

    Corresponding author
    1. Department of Surgery, University of Arizona College of Medicine, Tucson, Arizona
    • Professor of Surgery, Director of Student Research Programs, University of Arizona College of Medicine, 1501 N. Campbell Avenue, P.O. Box 245200, Tucson, AZ 85724-5200. Fax: +1-520-626-0822.
    Search for more papers by this author
    • Professor of Surgery, Director of Student Research Programs; President, Ignorance Foundation, Inc.


Abstract

In the elusive quest for “personalized” cancer treatments based on pharmacogenomics, diverse challenges must be overcome: questionable validity of “molecular models of life,” obstacles to bidirectional translation of scientific advances from bench to bedside to community, and limitations of bioinformatics to recognize and deal with “ignoramics/ignoromes” (expanding unknowns in cancer biology, theranostics, and therapeutic choices). These considerations apply to lymphatic system functioning—lymphatic vessels, lymph, lymph nodes, and lymphocytes—in diseases like cancer. J. Surg. Oncol. 2011;103:501–507. © 2011 Wiley-Liss, Inc.

Ancillary